OssDsign
Edit

OssDsign

https://www.ossdsign.com/
Last activity: 02.04.2024
Categories: UniversityTechnologyScienceSalesProductMedTechMarketCommerceAudioApp
OssDsign is a Swedish medtech company dedicated to creating regenerative implants for improved healing of bone defects. We provide surgeons and patients around the world with an expanding range of innovative implant solutions for improved patient outcomes. OssDsign’s technology is the result of collaboration between clinical researchers at the Karolinska University Hospital, Stockholm, and material science experts at the Ångström Laboratory at Uppsala University. In November 2020, OssDsign acquired Sirakoss, a Scottish company dedicated to developing the next generation nanosynthetic bonegraft substitute. Website: www.ossdsign.com Newsroom: https://news.cision.com/ossdsign-ab (Always consult Instructions for Use which accompany the products for complete indications, contraindications, warnings and precautions.)
Followers
355
Followers
1.26K
Mentions
34
Location: Sweden, Uppsala
Employees: 11-50
Total raised: $48.74M
Founded date: 2011

Investors 3

Funding Rounds 3

DateSeriesAmountInvestors
30.11.2022-$6.25M-
12.05.2021-$32.06M-
04.11.2015-$10.43M-

Mentions in press and media 34

DateTitleDescriptionSource
02.04.2024OssDsign awarded long-term agreement with Premier, Inc.OssDsign awarded long-term agreement with Premier, Inc. Tue, Apr 02, 2024 07:00 CET Report this cont...news.cisio...
06.02.2024OssDsign AB (publ) publishes year-end report 2023OssDsign AB (publ) publishes year-end report 2023 Tue, Feb 06, 2024 07:00 CET Report this content Ex...news.cisio...
21.11.2023OssDsign AB (publ) publishes Q3 2023 Interim ReportOssDsign AB (publ) publishes Q3 2023 Interim Report Tue, Nov 21, 2023 08:00 CET Report this content ...news.cisio...
16.10.2023Extraordinary General Meeting held in OssDsign ABExtraordinary General Meeting held in OssDsign AB Mon, Oct 16, 2023 11:00 CET Report this content To...news.cisio...
18.09.2023OssDsign® Catalyst receives clearance from FDA for major new...OssDsign® Catalyst receives clearance from FDA for major new indication for use in interbody cages M...news.cisio...
22.08.2023OssDsign AB (publ) publishes Q2 2023 Interim ReportOssDsign AB (publ) publishes Q2 2023 Interim Report Tue, Aug 22, 2023 08:00 CET Report this content ...news.cisio...
16.08.2023OssDsign surpasses 200 patients in its prospective spinal fu...OssDsign surpasses 200 patients in its prospective spinal fusion registry PROPEL Wed, Aug 16, 2023 0...news.cisio...
31.05.2023Annual General Meeting held in OssDsign ABAnnual General Meeting held in OssDsign AB Wed, May 31, 2023 13:30 CET Report this content Today, th...news.cisio...
23.05.2023OssDsign AB (publ) publishes Q1 2023 Interim ReportOssDsign AB (publ) publishes Q1 2023 Interim Report Tue, May 23, 2023 08:00 CET Report this content ...news.cisio...
09.05.20231,000 patients treated with OssDsign® Catalyst in the U.S.1,000 patients treated with OssDsign® Catalyst in the U.S. Tue, May 09, 2023 12:37 CET Report this c...news.cisio...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In